APTSTAT3-9R

Catalog No.S8197 Batch:S819701

Print

Technical Data

Formula

C223H330N80O51
Molecular Weight 4947.51 CAS No. no CAS
Solubility (25°C)* In vitro Water 100 mg/mL (20.21 mM)
DMSO 10 mg/mL (2.02 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description APTSTAT3-9R is a specific STAT3-binding peptide with addition of a cell-penetrating motif. The treatment of APTSTAT3-9R in various types of cancer cells blocks STAT3 phosphorylation and reduces expression of STAT targets.
Targets
STAT3 [1]
(In A549 cells)
In vitro APTSTAT3-9R effectively inhibited phosphorylation of STAT3 but did not affect the level of AKT phosphorylation and it suppresses cell viability and proliferation of cancer cells[1].
In vivo APTSTAT3-9R could effectively suppress tumor growth in the in vivo allograft and xenograft tumor models by inhibiting STAT3 phosphorylation[1].

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    A549 cells

  • Concentrations

    0-100 μmol/L

  • Incubation Time

    12 h

  • Method

    Cells are plated in a 96-well plate (5,000 cells/well) and incubated for 12 hours. After incubation the cells are treated with nine-arginine (9R), APTSTAT3-9R, and APRscr-9R for 12 hours. After 12 hours incubation, 20 μL MTT (5 mg/mL) is added to each well. After 4 hours, 100 μL dimethyl sulfoxide is added to each well, and absorbance is measured at 570 nm using a Spectra Macplus microplate reader
Animal Study:[1]
  • Animal Models

    Human lung carcinoma xenograft model(by subcutaneous implantation of A549 cancer cells into female BALB/c nude mice)

  • Dosages

    8 mg/kg

  • Administration

    intratumoral injection

Selleck's APTSTAT3-9R has been cited by 5 publications

Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation [ Hepatology, 2024, 10.1097/HEP.0000000000001003] PubMed: 38985995
Establishment and characterization of immortalized sweat gland myoepithelial cells [ Sci Rep, 2022, 12(1):7] PubMed: 34997030
Milk fat globule EGF factor 8 restores mitochondrial function via integrin-medicated activation of the FAK-STAT3 signaling pathway in acute pancreatitis [ Clin Transl Med, 2021, 11(2):e295] PubMed: 33634976
Curcumin reverses hepatic epithelial mesenchymal transition induced by trichloroethylene by inhibiting IL-6R/STAT3 [ Toxicol Mech Methods, 2021, 1-11] PubMed: 34233590
A novel human colon signet-ring cell carcinoma organoid line: establishment, characterization and application [ Carcinogenesis, 2020, 41(7):993-1004] PubMed: 31740922

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.